Clinical trials
Early Alzheimer's Disease clinical trials
Below are recruiting early alzheimer's disease clinical trials, each written for real people, not researchers. We’re tracking 108 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06297590RecruitingPhase 1
First human study of a new Alzheimer's drug
This study tests an experimental drug (LY3954068) for people with early Alzheimer's disease. It aims to see if the drug is safe and may slow memory loss. You'll need a PET scan to measure tau protein in the brain and have a study partner who can help attend appointments.
Maitland, FloridaAges 50–85 - NCT06322667Recruiting
Study of lecanemab in early Alzheimer's disease
This study tracks the real-world experience of people with early Alzheimer's disease who are already taking lecanemab. It aims to better understand how the medication works and its safety in everyday medical practice.
HiroshimaAges 18 years+ - NCT06362707RecruitingPhase 2
Fasudil trial for early Alzheimer's disease
This trial tests a medication called fasudil to see if it can help people with early Alzheimer's disease. It is for people who have early symptoms (mild cognitive impairment or mild dementia) and have biomarker evidence of Alzheimer's in their brain.
Tromsø, NordlandAges 50–100 - NCT06385951Recruiting
Virtual reality navigation test for early Alzheimer's detection
This study uses a virtual reality navigation task to detect early signs of Alzheimer's disease. It compares people with mild cognitive problems, mild Alzheimer's, and healthy older adults to see if this test can spot the disease earlier.
Ghent, East-FlandersAges 50–80 - NCT06489548RecruitingPhase 2
Foralumab for Early Alzheimer's Disease
This study tests an experimental drug called Foralumab, which aims to calm overactive immune cells in the brain linked to Alzheimer's. It may help slow memory loss in people with early-stage Alzheimer's.
Boston, MassachusettsAges 60–85 - NCT06539169Recruiting
Following people with rare diseases over time
This study follows people with rare diseases over time to learn more about how these conditions progress and how they are treated. Joining may help researchers understand your disease better and find better ways to care for others.
Los Altos, CaliforniaAges Any age - NCT06565143Recruiting
Brain stimulation for early Alzheimer's disease
This trial tests whether a gentle, non-invasive electrical brain stimulation method called tACS can help people in the early stages of Alzheimer's disease. You may be eligible if you have mild cognitive impairment or early dementia and have been on a common Alzheimer's medication for at least 3 months.
Hefei, AnhuiAges 50–85 - NCT06566170Recruiting
Donanemab for early Alzheimer's: a real-world study
This study compares donanemab plus usual care to usual care alone for people with early Alzheimer's symptoms, to see how well donanemab works in everyday life. You may be able to join if you have early memory or thinking problems and have a brain scan or blood test showing Alzheimer's-related changes.
Huntsville, AlabamaAges 60 years+ - NCT06584357Recruiting
Digital and blood markers linked to brain scans in older adults
This study is looking for older adults (60–90) who are either cognitively normal, have mild cognitive impairment (MCI), or have mild-to-moderate Alzheimer's dementia. It aims to see how digital tests and blood-based markers relate to brain scans (amyloid and tau PET). You will need a study partner, undergo MRI and PET scans, and give blood samples.
Atlantis, FloridaAges 60–90 - NCT06657768RecruitingPhase 1
Study of LY4006895 for healthy people and those with early Alzheimer's
This trial tests a new medicine called LY4006895 in two groups: healthy volunteers and people with early symptomatic Alzheimer's disease. It aims to see how the drug works in the body and if it might help memory and thinking.
Los Alamitos, CaliforniaAges 45–85 - NCT06668610Recruiting
Brain stimulation study for mild memory problems
This study tests a non-invasive brain stimulation technique (tDCS) combined with brain wave recording (EEG) to see if it can improve memory and thinking in people with mild cognitive impairment or early dementia.
Caserta, ItalyAges 55–85 - NCT06688968Recruiting
Music, thinking, and memory in Parkinson's and Alzheimer's
This study looks at how music engagement affects thinking and memory in people with Parkinson's or Alzheimer's disease. It may help researchers understand how music can support brain health as we age.
Montpellier, HéraultAges 60 years+ - NCT06741553Recruiting
Studying lecanemab for early Alzheimer's disease
This study looks at how well lecanemab works for people with early Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
Hangzhou, ZhejiangAges Up to 85 years - NCT06833645Recruiting
PET scans to spot early Alzheimer's changes
This trial uses special PET scans to see amyloid and tau proteins in the brain, which are linked to Alzheimer's. It aims to find these changes early, in people with mild memory problems or early-stage Alzheimer's.
Chengdu, SichuanAges 18 years+ - NCT06841848Recruiting
Eye camera test for early Alzheimer's
This study is testing a new eye camera to see if it can help find early signs of Alzheimer's disease. It is for people aged 55 and older who either have mild to moderate Alzheimer's or do not have Alzheimer's.
Rome, ItalyAges 55 years+ - NCT06850597RecruitingPhase 2
Testing dimethyl fumarate for early Alzheimer's disease
This study tests a drug called dimethyl fumarate to see if it can help people with early Alzheimer's disease. It may slow down memory loss and thinking problems.
Lodz, Łódź VoivodeshipAges 55–90 - NCT06852352Recruiting
Modified brain lymph surgery for Alzheimer's or Parkinson's
This study tests a new, less invasive surgery to improve lymph drainage from the brain. It may help clear harmful proteins linked to Alzheimer's or Parkinson's disease.
Hangzhou, ZhejiangAges 50–80 - NCT06883019Recruiting
Lecanemab for early onset inherited Alzheimer's
This trial tests a medication called lecanemab for people with early onset familial Alzheimer's disease. It aims to see if the drug can help slow cognitive decline in those with confirmed signs of Alzheimer's in their brain.
Beijing, ChinaAges 18–65 - NCT07036328Recruiting
Magnetic brain stimulation to slow memory loss in Alzheimer's
This study tests whether a noninvasive magnetic brain stimulation treatment can slow down cognitive decline in people with early Alzheimer's disease. You'll receive daily sessions over several weeks, and the goal is to see if it helps preserve memory and thinking skills.
AmsterdamAges 50–85 - NCT07094516RecruitingPhase 2
Testing VHB937 for early Alzheimer's disease
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
Phoenix, ArizonaAges 50–85 - NCT07105709RecruitingPhase 2
Extension study for early Alzheimer's treatment
This study is a follow-up for people who completed a previous trial of an experimental treatment for early Alzheimer's disease. It will continue to test the treatment's safety and effects over a longer period.
Maitland, FloridaAges 50–85 - NCT07169578RecruitingPhase 3
A study of trontinemab for early Alzheimer's disease
This trial tests a new drug called trontinemab for people with early Alzheimer's disease. The goal is to see if it can help slow down memory and thinking problems.
Birmingham, AlabamaAges 50–90 - NCT07170150RecruitingPhase 3
A study of trontinemab for early Alzheimer's disease
This trial tests an investigational drug called trontinemab in people with early symptomatic Alzheimer's disease. It aims to see if it can slow down memory and thinking problems.
Phoenix, ArizonaAges 50–90 - NCT07221344RecruitingPhase 1/Phase 2
Study of an experimental drug for early Alzheimer's disease
This study tests an investigational drug, ARO-MAPT-SC, which targets a protein involved in Alzheimer's disease. It is for people with early Alzheimer's to see if the drug is safe and can slow the disease.
East York, OntarioAges 18–80
Hear when a new Early Alzheimer's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for early alzheimer's disease?
- Yes. Clin2 currently lists 108 recruiting early alzheimer's disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a early alzheimer's disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a early alzheimer's disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.